Abstract
Viral DNA integration into the infected cell genome is an essential step in the HIV-1 life cycle. Hence, the viral integrase enzyme has become an important target for antiviral therapy. The integrase's activity action relies on the binding to its cellular partners, therefore the knowledge of the structural determinants is very important from a therapeutic perspective. Here we first review published computer-aided structural predictions of HIV-1 integrase in complex with its interactors. These include DNA and the human HAT protein. Next, we present a prediction of the complex between HIV-1 integrase with the human prolyl-isomerase-1 (hPin1) enzyme. Interaction with hPin1 is crucial for efficient HIV-1 infection and it increases integrase stability (Manganaro et. al 2010, Nat. Med. 16, 329). The modeling presented here, which is validated against experimental data, provides a rationale for a variety of viral protein's mutations which impair protein function and HIV-1 virus replication in vivo without significantly affecting enzymatic activity.
Keywords: HIV-1 integrase, human Pin1, protein – protein interaction, class II mutant.
Current Pharmaceutical Design
Title:HIV-1 Integrase Binding to its Cellular Partners: A Perspective from Computational Biology
Volume: 20 Issue: 21
Author(s): Vo Cam Quy, Vincenzo Carnevale, Lara Manganaro, Marina Lusic, Giulia Rossetti, Vanessa Leone, Cristina Fenollar-Ferrer, Simone Raugei, Giannino Del Sal, Mauro Giacca and Paolo Carloni
Affiliation:
Keywords: HIV-1 integrase, human Pin1, protein – protein interaction, class II mutant.
Abstract: Viral DNA integration into the infected cell genome is an essential step in the HIV-1 life cycle. Hence, the viral integrase enzyme has become an important target for antiviral therapy. The integrase's activity action relies on the binding to its cellular partners, therefore the knowledge of the structural determinants is very important from a therapeutic perspective. Here we first review published computer-aided structural predictions of HIV-1 integrase in complex with its interactors. These include DNA and the human HAT protein. Next, we present a prediction of the complex between HIV-1 integrase with the human prolyl-isomerase-1 (hPin1) enzyme. Interaction with hPin1 is crucial for efficient HIV-1 infection and it increases integrase stability (Manganaro et. al 2010, Nat. Med. 16, 329). The modeling presented here, which is validated against experimental data, provides a rationale for a variety of viral protein's mutations which impair protein function and HIV-1 virus replication in vivo without significantly affecting enzymatic activity.
Export Options
About this article
Cite this article as:
Quy Cam Vo, Carnevale Vincenzo, Manganaro Lara, Lusic Marina, Rossetti Giulia, Leone Vanessa, Fenollar-Ferrer Cristina, Raugei Simone, Sal Del Giannino, Giacca Mauro and Carloni Paolo, HIV-1 Integrase Binding to its Cellular Partners: A Perspective from Computational Biology, Current Pharmaceutical Design 2014; 20 (21) . https://dx.doi.org/10.2174/13816128113199990631
DOI https://dx.doi.org/10.2174/13816128113199990631 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dietary Phytochemicals in Chemoprevention of Cancer: An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) Anticancer Drugs Discovery and Development from Marine Organisms
Current Topics in Medicinal Chemistry Aurora Kinase Inhibitors in Head and Neck Cancer
Current Topics in Medicinal Chemistry Perinatal Gene Transfer to the Liver
Current Pharmaceutical Design Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy
Current Pharmaceutical Biotechnology Tubulin-Targeting Agents in Hybrid Drugs
Current Medicinal Chemistry Roles of p97-Associated Deubiquitinases in Protein Quality Control at the Endoplasmic Reticulum
Current Protein & Peptide Science Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewing’s Sarcoma Tumor Cells
Current Pharmaceutical Biotechnology Texaphyrins: Tumor Localizing Redox Active Expanded Porphyrins
Anti-Cancer Agents in Medicinal Chemistry Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Current Cancer Drug Targets Interferons: Mechanisms, Biological Activities and Survey of their Use in Human Diseases
Current Bioactive Compounds Recent Advances in Metabolic Profiling and Imaging of Prostate Cancer
Current Metabolomics CSPG4 in Cancer: Multiple Roles
Current Molecular Medicine Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Markov-Randic Indices for QSPR Re-Evaluation of Metabolic, Parasite- Host, Fasciolosis Spreading, Brain Cortex and Legal-Social Complex Networks
Current Bioinformatics Green Chemistry Approach as a Versatile Platform for Nanoparticles with Biomedical Applications
Nanoscience & Nanotechnology-Asia Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics Anticancer Drugs in Liposomal Nanodevices: A Target Delivery for a Targeted Therapy
Current Topics in Medicinal Chemistry Helicase Domain Containing Proteins in Human Disorders
Current Genomics